The scope of targeted tumor cells primarily encompasses hematological malignancies (including B-cell malignancies targeted by CD19) and solid tumors (such as epidermal growth factor receptor [EGFR] or programmed cell death ligand 1[PD-L1]-positive tumors). This evidence concerns the gene EGFR and neoplasm.